SINOVAC Varicella Vaccine Prequalified by WHO
November 03 2022 - 10:03PM
Business Wire
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA),
a leading provider of biopharmaceutical products in China, today
announced that it received prequalification from the World Health
Organization (WHO) for its live attenuated varicella vaccine on
November 3, 2022. This marks the first WHO prequalified Chinese
varicella vaccine and the fourth SINOVAC vaccine to receive WHO
approval.
The varicella vaccine is derived from the Oka strain and
propagated in SINOVAC’s proprietary Human Diploid Cell (SV-1
strain), which is made by culturing and harvesting the virus,
adding stabilizers and freeze-drying.
According to a phase III efficacy study, the seroconversion rate
of the vaccinated children group, ages 1 to 12 years old, was
97.1%; the efficacy of the vaccine was 87.1% against varicella and
89.2% for breakthrough varicella. The vaccine provides 100%
protection against moderate and severe cases.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac,
commented, “Now that SINOVAC has received WHO prequalification for
our varicella vaccine, we can provide a new weapon for prevention
and control of infectious diseases globally. In the future, we will
continue to work on more clinical trials, registrations and
approvals for vaccines worldwide, to offer the world high-quality
vaccines and ensure the accessibility and affordability of these
public goods.”
Previously, three other vaccines by SINOVAC were also approved
by WHO in various uses and conditions, including Healive® (the
hepatitis A vaccine), CoronaVac® (the COVID-19 vaccine) and the
Sabin-strain inactivated polio vaccine.
SINOVAC has been acting on its mission to “Supply Vaccines to
Eliminate Human Diseases”. So far, SINOVAC’s vaccines have been
distributed to more than 80 countries and regions around the world.
The Company offers high-quality and affordable vaccines for global
prevention and control of infectious diseases.
About SINOVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based
biopharmaceutical company that focuses on the R&D,
manufacturing, and commercialization of vaccines that protect
against human infectious diseases.
SINOVAC’s product portfolio includes vaccines against COVID-19,
enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD),
hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1
pandemic influenza (avian flu), H1N1 influenza (swine flu),
varicella, mumps, poliomyelitis, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in
more than 60 countries and regions worldwide. The hepatitis A
vaccine, Healive®, passed WHO prequalification requirements in
2017. The EV71 vaccine, Inlive®, is an innovative vaccine
commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain
inactivated polio vaccine (sIPV) and varicella vaccine were
prequalified by the WHO.
SINOVAC was the first company to be granted approval for its
H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese
government's vaccination campaign and stockpiling program. The
Company is also the only supplier of the H5N1 pandemic influenza
vaccine, Panflu®, to the Chinese government stockpiling
program.
SINOVAC continually dedicates itself to new vaccine R&D,
with more combination vaccine products in its pipeline, and
constantly explores global market opportunities. SINOVAC plans to
conduct more extensive and in-depth trade and cooperation with
additional countries, and business and industry organizations.
For more information, please see the Company’s website at
www.sinovac.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221103006414/en/
Sinovac Biotech Ltd. PR Team pr@sinovac.com
IR Team ICR Inc. Bill Zima U.S.: 1-646-308-1707
william.zima@icrinc.com
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Apr 2023 to Apr 2024